The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

The combination is intended to treat subjects with newly diagnosed pancreatic ductal adenocarcinoma. Credit: SewCreamStudio/Shutterstock. The Paul-Ehrlich-Institute ...

JP Morgan attendees were told of Jazz Pharmaceuticals' plans to expand indications for two oncology drugs: zanidatamab and ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting gynaecologic and testicular cancers.

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of PH284 for the treatment of cancer cachexia.

Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's MHRA for its small molecule therapeutic, PTD802.